Related Experiment Video
Updated: May 22, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Development and Characterization of Three Novel FGFR Inhibitor Resistant Cervical Cancer Cell Lines to Help Drive
Nauf Bou Antoun1, Hiba-Tun-Noor Afshan Mahmood1, Anthony J Walker1
1School of Life Sciences Pharmacy and Chemistry, Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK.
Abstract:
Primary or acquired resistance to therapeutic agents is a major obstacle in the treatment of cancer patients. Cervical cancer is the fourth leading cause of cancer deaths among women worldwide and, despite major advances in cancer screening and treatments, many patients with advanced stage cervical cancer have a high recurrence rate within two years of standard treatment, with drug resistance being a major contributing factor. The development of cancer cell lines with acquired resistance to therapeutic agents can facilitate the comprehensive investigation of resistance mechanisms, which cannot be easily performed in clinical trials. This study aimed to create three novel and robust cervical cancer cell lines (HeLa, CaSki, and SiHa) with acquired resistance to a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor (PD173074). All three drug-resistant (DR) cell lines overexpressed FGFR1, FGFR2, FGF2, FGF4, and FGF7 proteins that were also localized to the nucleus. In addition, the DR cells had a significantly more aggressive phenotype (more migratory and proliferative, less apoptotic) compared to the parental cell lines. These novel DR cervical cancer cells are a critical tool for understanding the molecular mechanisms underpinning drug resistance and for the identification of potential cervical cancer biomarkers. Moreover, the availability of such DR cell lines may facilitate the development of more effective therapeutic strategies using FGFR inhibitors in combination with other agents that target pathways responsible for acquired resistance to FGFR inhibitors.
Insights
Researchers developed new drug-resistant cervical cancer cell lines. These models overexpress fibroblast growth factor receptor (FGFR) proteins, aiding study into resistance mechanisms and potential biomarkers for improved cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Acquired resistance to cancer therapies is a significant clinical challenge.
- Cervical cancer, particularly advanced stages, exhibits high recurrence rates due to drug resistance.
- Investigating resistance mechanisms in vitro is crucial for developing effective treatments.
Purpose of the Study:
- To generate novel cervical cancer cell lines with acquired resistance to a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
- To characterize the molecular and phenotypic changes associated with drug resistance in these cell lines.
- To provide valuable tools for studying drug resistance mechanisms and identifying potential biomarkers.
Main Methods:
- Development of drug-resistant (DR) cell lines from HeLa, CaSki, and SiHa cervical cancer cell lines using PD173074 (an FGFR tyrosine kinase inhibitor).
- Analysis of protein expression (FGFR1, FGFR2, FGF2, FGF4, FGF7) and localization in parental and DR cell lines.
- Assessment of phenotypic characteristics, including migration, proliferation, and apoptosis, in parental and DR cells.
Main Results:
- Three novel, robust cervical cancer cell lines (HeLa, CaSki, SiHa) acquired resistance to PD173074.
- DR cell lines exhibited overexpression and nuclear localization of FGFR1, FGFR2, FGF2, FGF4, and FGF7.
- DR cells displayed a significantly more aggressive phenotype: increased migration and proliferation, and decreased apoptosis.
Conclusions:
- The novel drug-resistant cervical cancer cell lines are essential tools for understanding acquired resistance mechanisms.
- These cell lines can facilitate the identification of biomarkers for cervical cancer.
- The availability of these models may aid in developing combination therapies targeting FGFR pathways and resistance mechanisms.
Related Concept Videos
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle